BP’s Phathom Pharmaceuticals PHAT Stock Holding History

BP’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-23,000	Closed	-$753K	–	541
2020 Q2	$753K	Buy	+23,000	New	+$884K	0.03%	466

Other funds holding PHAT

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BP's PHAT Position: Q3 2020 in Review

BP sold out of Phathom Pharmaceuticals (PHAT) in Q3 2020, closing a stake of 23,000 shares — an estimated $753K sold.

BP first reported a position in PHAT in Q2 2020 and held it in 1 quarter. The position peaked at $753K in Q2 2020. 58 funds tracked by Wall St. Rank hold PHAT as of Q3 2020.

BP reported no remaining Phathom Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
BP sold 23,000 Phathom Pharmaceuticals shares in Q3 2020, an estimated $753K.
BP first reported a position in Phathom Pharmaceuticals in Q2 2020 and held it in 1 quarter.
BP's Phathom Pharmaceuticals position peaked at $753K in Q2 2020.
58 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2020.

Based on BP's 13F filing for Q3 2020, filed 30 Oct 2020.